ArticleNature communications2026
cfGWAS reveal genetic basis of cell-free DNA end motifs.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free DNA (cfDNA) consists of degraded DNA fragments released into body fluids. Its genetic and pathological information makes it useful for prenatal testing and early tumor detection. However, the mechanisms behind cfDNA biology are largely unknown. In this study, for the first time, we conduct a genome-wide association study (GWAS) to explore the genetic basis of cfDNA end motif frequencies, termed cfGWAS, in 28,016 pregnant women. We identify 15 study-wide significant loci, including the well-known cfDNA-related genes DFFB and DNASE1L3, as well as novel genes potentially involved in cfDNA biology, such as PANX1 and DNASE1L1. The findings are further verified through three independent GWAS studies and experimental validation in knockout mice and cell lines. Subsequent analyses reveal strong causal relationships of leukocytes, especially neutrophils, with cfDNA features. In summary, we introduce the cfGWAS, revealing the genetic basis of cfDNA biology on a genome-wide scale. Novel knowledge uncovered by this study promises to revolutionize liquid biopsy technology and lead to potential new drugs targeting certain diseases. Given that millions of cfDNA whole genome sequencing data have been generated from clinical testing, the potential of this paradigm is enormous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.